Elevance (NYSE: ELV) CFO trims stake 34.7% in insider stock sale

What happened

Elevance Health, Inc. (NYSE: ELV) said EVP & CFO Mark Kaye sold 10,584 shares on 2026-10-22. The Form 4 lists 13 common-stock sales executed in multiple trades, with weighted-average prices from $434.00 to $447.19 per share. The report was filed on 2026-10-23.

After the trades, Kaye held 19,919 shares in direct ownership. The filing's explanation says each line reflects a weighted-average price for a separate lot. No derivative securities changed hands, and the report lists direct ownership.

Key numbers

Metric	Latest	Change	Source
Shares sold	10,584 shares		SEC Form 4
Sale price range	$434.00 to $447.19 per share		SEC Form 4
Sale proceeds	about $4.66 million		SEC Form 4
Shares held after sale	19,919 shares		SEC Form 4

Read more: Elevance Health (ELV) stock analysis and investment case

Why it matters

OptimistFi's case is that Elevance converts scale in premium volume into underwriting earnings only if it sustains medical-cost discipline and cash conversion. This filing weakens that case a bit because it shows the CFO reducing a direct stake rather than posting a business result. Kaye sold 10,584 shares, about 34.7% of the 30,503 shares held before the trade.

The sale brought in about $4.66 million, while 19,919 shares remained in direct ownership. That means the position was trimmed, not exited. The size matters for insider alignment, but the filing is still only an ownership report.

The sale was spread across 13 lots, so the report uses weighted-average prices rather than one trade price. The first lot was 400 shares at $434.00 and the last lot was 273 shares at $447.19. Investors get a clearer picture of insider exposure, not a new read on earnings.

Elevance investors will care more about the next operating release than this one-day sale. The Form 4 changes the insider picture, but it does not change the company's earnings path. That is the key distinction.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

The next quarterly report will matter more for the thesis than this Form 4. A stronger margin update would support the case, while weaker cash conversion would pressure it. That report will be the next scheduled check on medical-cost discipline. It will show whether the operating story is improving faster than insider selling suggests. That is what will matter next.

More from OptimistFi

• ELV stock: the Elevance Health thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps